Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Guardant Health, Inc. filings document a Nasdaq-listed precision oncology company that reports results for Oncology, Screening, and Biopharma & Data activities. Its 8-K filings furnish quarterly and annual financial results, preliminary financial information, Regulation FD presentation materials, material agreements, officer changes, and securities offering disclosures.
The company’s proxy materials cover annual meeting voting matters, board and governance information, executive compensation and stockholder proposals. Registration and offering-related filings describe common stock issuance under a shelf registration statement, while recurring disclosures address capital structure, operating outlook, clinical and regulatory updates, and the use of its blood and tissue testing portfolio.
Guardant Health, Inc. Co-Chief Executive Officer Helmy Eltoukhy reported a series of open-market sales of the company’s common stock on June 5, 2026. Through the Helmy A. Eltoukhy Revocable Trust, he sold a total of 100,000 shares in seven transactions at weighted average prices between about $124.95 and $132.55 per share. Following these sales, the trust continues to hold approximately 2,063,203 shares of Guardant Health common stock indirectly attributed to Eltoukhy.
Guardant Health, Inc. Chief Financial Officer Michael Brian Bell sold 2,000 shares of common stock in an open-market transaction. The shares were sold at a weighted average price of $128.6203 per share. Following this sale, he directly holds 47,509 shares of Guardant Health common stock.
The footnote explains that the sale occurred through multiple trades at prices ranging from $128.620 to $128.955 per share, and detailed trade-level information is available upon request.
Guardant Health director Steve E. Krognes sold shares in an open-market transaction. He sold 9,294 shares of Guardant Health common stock on June 4, 2026 at a weighted average price of $132.5072 per share, in multiple trades priced between $132.50 and $132.71. After this sale, he directly owns 10,222 Guardant Health shares.
GH submitted a Form 144 notice via Stifel Nicolaus & Company Inc reporting proposed sales of Common Stock consisting of multiple Restricted Stock Units scheduled on specific grant/settlement dates. The filing lists discrete RSU lots and share counts tied to dates from 03/12/2025 through 03/13/2026.
Guardant Health reports a Form 144 filing listing 2,000 shares to be sold. The filing names Charles Schwab & Co., Inc. as the broker and records a prior sale of 3,000 shares on 03/16/2026.
The shares are described as tied to a Performance Stock Lapse from 02/01/2025
Guardant Health, Inc. director Meghan V. Joyce reported option exercises and related share sales. On June 3, 2026, she exercised stock options to acquire a total of 10,000 shares of Guardant Health common stock at exercise prices of $38.005 and $38.420 per share.
On the same date, she executed open-market sales totaling 10,000 shares of common stock in multiple price tranches, at weighted average prices reported around the high $120s per share. Following these transactions, she directly holds 11,183 shares of Guardant Health common stock, and the exercised option positions have been fully converted into shares.
Guardant Health, Inc. director Steve E. Krognes reported a routine equity compensation event involving 154 shares. He exercised restricted stock units into 154 shares of Common Stock, classified as a derivative exercise rather than an open-market purchase or sale. Following this transaction, he holds 19,516 shares of Common Stock directly and 155 Restricted Stock Units.
The RSUs come from an award granted on August 9, 2022 that vested 25% of the shares on June 30, 2023, with the remaining 75% vesting in substantially equal monthly installments over three years. No shares were sold, gifted, or withheld for taxes in this filing.
Guardant Health, Inc. director Manuel Hidalgo Medina reported an open-market sale of 1,000 shares of Common Stock at an average price of $130.0601 per share. After this transaction on May 28, 2026, he directly holds 639 shares of Guardant Health common stock.